资讯  教育  校园  房产  旅游  娱乐  科技  健康  财经  体育  消费  文史  书画  能源

  RSS 设为首页   加入收藏
首页 > 文传商讯 > 正文

Shinkowa Pharmaceutical Launches a Research to Scientifically Substantiate Biological Safe Material,

时间:2020-04-22 12:40:00  来源:文传商讯  作者:
 

We are the company that will achieve productive aging worldwide, delivering wellness science based on research evidence.

TOKYO--()--Shinkowa Pharmaceutical Co., Ltd. (Head Office: Tokyo Chuo-Ward, CEO: Megumi Tanaka) is the largest nutraceutical (health supplemental food which is scientifically proved) producer of β-nicotinamide mononucleotide (NMN) blended nutraceutical, which is effective to maintain health and longevity, providing high-purity NMN to universities and researchers both domestic and foreign.
It launches a research to scientifically substantiate biological safe material, NMN’s effect of improving immune system as an infection control measure of COVID-19 and other infections. And our goal is to apply the research result to prevent and treat infections.

Our in-house research laboratory, Life Science Lab has confirmed that expression level increases at the level of protein in longevity gene or so-called anti-aging gene such as Sirtuin 1, and quantity of mitochondria which reforms nutrition in cells to energy effectively when we add NMN appropriately to human cells in culture solution.
The result scientifically shows that our product, NMN fully uses enormous types of genes which are embedded in human genome via adjustment by Sirtuin 1 and maintain the intracellular mechanism by circulating energy exhaustively at the same time.

The above result strongly suggests a possibility that NMN can reinforce immunity when it effects immune system cells (lymphocytic T cell etc.)

We are now engaging in an experiment to observe how CD4+ helper T cell and CD8+ killer T cell, which is the main immunity system against infections, will be adjusted appropriately by NMN to look for a way to apply NMN as precaution and treatment of infections. The experiment is conducted under conditions that imitates various human body where T cell functions such as in bloodstream, capillary vessel and infiltration system with special facilities which can cultivate cells. We are also analyzing how T cell reacts to NMN under specific body’s internal environment and its molecular mechanism.

Many research institutes and hospitals are encouraging people to strengthen immunity since effective treatments, remedies and vaccines for COVID-19 have not been developed yet.
It is empirically supposed that taking enough sleep, meals (alimentation), exercise and stress minimization have certain effect on reinforcing immunity. However, these are not supported by scientific point of view. Moreover, it is not easy to practice these recommendations perfectly under the quarantine to restrain COVID-19 to spread.

We have been consistently analyzing and practicing the in vivo mechanism that taking NMN-blended nutraceutical (health supplemental food which is scientifically proved. It is said that it has higher reliability than any supplement) can resist so-called immune deficiency, a continuous and indulgent physical disorder but which has not been regarded as an illness either as a healthy condition.

In the midst of these ongoing efforts and facing the current pandemic of COVID-19, we are accelerating our research aimed at improving the immune system to prevent viral infections and severe illness.

The research is cooperated with The System Biology Institute (Representative ; Dr. Kitano Hiroaki) to lead a research of control and preventive effect against allergy, inflammation, cytokine storm (severe shock-like conditions caused by a runway immune system) and mainly pulmonary disease. (It is reported on a recent paper on The Lancet, one of the 5 prestigious medical journals that cytokine storm is highly related to worsen COVID-19 patients’ condition.)

Besides, we have decided to launch a new clinical trial as a pilot study with medical research institutes to observe various parameters related to immunity such as the number of CD8+ killer T cell in human (tester) blood, specification of the number of type and quantity of cells in the tester’s intestinal flora at the species level to confirm those parameters can be increased by taking NMN.

This trial aims to analyze improvements which are based on the test result precisely and to obtain scientific evidence by improving physical disorders and prevention and reinforcing immunity to prove human’s potential strength which can contribute to preventions of epidemics.
And the result of the trial is expected to be disclosed and used effectively by various research institutes.

We established a reputation as pioneer of NMN bio-venture company which conducted the first NMN clinical trial with human body, launched various science-based products, and in charge of both research and sales. We are also aiming to contribute to the society by improving Quality Of Life.

Our NMN is well known as its high purity and stability, which is over 99%, and its safety is tested both with human and rodent. There are only 2 companies in the world who produces such high quality NMN including Shinkowa Pharmaceutical.

Achievements of Shinkowa Pharmaceutical regarding our Field of Research

 
 
 
上一篇:加快推进新形势下汽车金融合规化、线上化发展!
下一篇:I Squared Capital向丸红出售台湾最大太阳能平台
 
 
 
 
推荐资讯
中国浓香白酒核心产区沉淀一杯出“大国浓香”五粮液
中国浓香白酒核心产区
电影《钢铁意志》今日全国公映 青年歌唱家汤非献唱主题曲
电影《钢铁意志》今日
长安马自达好不好 恩施消费者有话说
长安马自达好不好 恩施
年轻人的座驾 创酷RS恩施受追捧
年轻人的座驾 创酷RS恩
栏目更新
栏目热门
 
 

 
 
网站声明 | 网站简介 | 网站导航 | 频道招商 | 联系方式 | 友情链接
www.hlwang.net 华鲁网